Frontlight ResearchEarly access
Taking people in United StatesPhase 2/3
Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts
Key facts
- Who runs it
- Western Institute for Veterans Research
- Where
- Salt Lake City, United StatesSee the 2 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 120 people, planned
- Started
- 25 Mar 2024
- Expected to end
- Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Human Papillomavirus 9-valent Vaccine, Recombinant
- Normal Saline
- Record updated
- 5 April 2024
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Must be able to understand and provide written informed consent
- Age 18 or older
- Clinical diagnosis of cutaneous warts
- Must have received prior treatment for cutaneous warts (such as curettage, cryotherapy, salicylic acid, intralesional Candida antigen injection, etc.)
Who cannot take part
- Active acute illness
- Known hypersensitivity to HPV vaccination
- Untreated cutaneous warts
- Anogenital warts
- Oral warts
- Treatment for cutaneous warts in the past 4 weeks
- Immunosuppression
- Subjects may not receive any other investigational treatment
- Pregnancy or planned pregnancy during the study period
This trial is currently available in United States.
- University of Utah Midvalley Health CenterSalt Lake City, United StatesContact: Lowell Nicholson, MDTaking people
- VA Salt Lake City Health Care SystemSalt Lake City, United StatesContact: Jamie Rhoads, MDTaking people
About the trial
What the trial wants to find out
This double-blinded clinical trial randomly assigns participants with refractory cutaneous warts to receive either treatment with the human papillomavirus (HPV) vaccine or a placebo to assess the efficacy of HPV vaccination for the treatment of refractory cutaneous warts.
The 2 groups in the trial
- HPV VaccineTreatment being tested
0.5-mL suspension of 9-valent Gardasil vaccine administered as intramuscular injection at weeks 0, 4, and 20
Treatment: Human Papillomavirus 9-valent Vaccine, Recombinant
- PlaceboPlacebo, for comparison
0.5-mL normal saline administered as intramuscular injection at weeks 0, 4, and 20
Treatment: Normal Saline
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Human Papillomavirus (HPV) Vaccination for the Treatment of Refractory Cutaneous Warts: A Randomized, Placebo-Controlled, Double-Blinded Trial
- Record updated
- 5 April 2024